Outer Biosciences’ living tissue platform keeps human skin viable for up to a month outside the body, then feeds every observation into an AI model that predicts which untested compounds are likely to do something useful. That loop, quietly assembled over several years in a lab just outside Cambridge, Massachusetts, is only now becoming public knowledge.
The company was co-founded by Michael Polansky (CEO), chief scientist Kyung-Jin Jang, CTO Chris Hinojosa, and chief business officer Stanley King. Its founding year carries a caveat worth flagging: the snippet gives 2022 as the formal co-founding date, while BioPharma Dive reports the company was formed in 2020. The discrepancy likely reflects the gap between when the work began and when the corporate entity was formally constituted.
What Outer Biosciences’ living tissue system actually does
The standard industry benchmark for keeping excised skin alive is a matter of days, long enough to screen for acute toxicity but not to observe slower processes such as collagen remodelling, pigmentation change, or barrier repair, all of which unfold over weeks. Outer Biosciences’ proprietary nutrient-and-waste-removal system extends that window to up to 30 days, with the tissue retaining what Polansky describes as its day-zero architecture and molecular programmes throughout.
The tissue itself comes from skin that would otherwise be discarded after surgery, mostly plastic surgery, sourced through vetted non-profit and commercial biobanks including the National Disease Research Interchange and the Cooperative Human Tissue Network. Every sample arrives de-identified. The company spent roughly two years building that supply pipeline and the protocols required to receive tissue within hours of surgery.
According to BioPharma Dive, the platform has to date generated more than 10 terabytes of data from more than 300 donors and over 10,000 compound-sample pairings, with each pairing producing more than 30,000 data points. That is a genuinely proprietary dataset: unlike AI companies training on scraped internet text, there is no biology internet to scrape.
The discovery loop works like this. An AI system the company calls Yuna, named in a Bioxconomy report, predicts which untested compounds are likely to affect a specific skin function. Those compounds run through the living-tissue system. Results, whether the prediction proved right or wrong, feed back into the model. The cycle then repeats, ideally faster and with better guesses each time.
Early on, Outer Biosciences relied on a more laborious approach, mining scientific literature and partnering with the National Cancer Institute on natural compounds from extreme environments. That phase produced a couple of leads over about 18 months. With AI in the loop, the company is now generating a new candidate roughly every six weeks, with six leads currently active and several dozen additional hits logged. Four of those six current leads look likely to reach commercialisation, Polansky says.
The market it is entering, and who else is in the race
The addressable universe here is smaller than you might expect. The FDA maintains rules covering 13 categories of over-the-counter skin drugs. Across all of them, only about 120 to 130 active ingredients are formally approved. Add cosmetic ingredients with meaningful research behind them and the number rises to around 200. Outer Biosciences is discovering cosmetic ingredients rather than regulated drugs, so the route to market runs through standardised industry naming and safety testing under OECD guidelines, not FDA approval. A licensing or sale arrangement with an established beauty or pharma company then takes care of formulation and distribution.
The company has raised roughly $23 million to date. Early backers include Wing Ventures, Initialized, and Polansky’s own venture firm, Hawktail, which BioPharma Dive says he established in 2021. The wider investor syndicate also includes Sozo Ventures, Lightspeed Venture Partners, Third Kind Venture Capital, Liquid 2 Ventures, and SV Angel, according to FinSMEs. The company employs 19 people.
Before Outer Biosciences, Polansky spent years running Sean Parker’s family office and helping stand up the Parker Institute for Cancer Immunotherapy, where he holds the title of Executive Director, Parker Foundation, per the Parker Institute’s leadership page.
The most direct competitor is Philadelphia-based Vivodyne, which pairs lab-grown human organ tissue with predictive AI to replace animal drug testing. Vivodyne’s $38 million seed round closed in November 2023, led by Khosla Ventures, according to Vivodyne’s own announcement. A subsequent $40 million Series A, also led by Khosla Ventures, brought in new backers including Lingotto Investment Management, Helena Capital, and Fortius Ventures alongside existing investors, per Business Wire. That capital will fund a new 23,000-square-foot fully robotic laboratory in the Brisbane/South San Francisco area, the Philadelphia Inquirer reports.
The distinction Outer Biosciences draws is its use of genuine post-surgical human tissue rather than engineered synthetic constructs. Whether that edge holds as competitors scale up their own platforms is the question the next few years will answer, probably around the time the first Outer Biosciences-derived ingredient lands on a shelf.
